C. Janus, J. Pearson, and J. Mclaurin, A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, vol.408, issue.6815, pp.979-82, 2000.

D. Morgan, D. M. Diamond, and P. E. Gottschall, A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, vol.408, issue.6815, pp.982-987, 2000.

D. Schenk, R. Barbour, and W. Dunn, Immunization with amyloid-beta attenuates

, Alzheimer-disease-like pathology in the PDAPP mouse, Nature, vol.400, issue.6740, pp.173-180, 1999.

S. Gilman, M. Koller, and R. S. Black, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, vol.64, issue.9, pp.1553-62, 2005.

J. M. Orgogozo, S. Gilman, and J. F. Dartigues, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology, vol.61, issue.1, pp.46-54, 2003.

C. Holmes, D. Boche, and D. Wilkinson, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, vol.372, issue.9634, pp.216-239, 2008.

B. Winblad, N. Andreasen, and L. Minthon, Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study, Lancet Neurol, vol.11, issue.7, pp.597-604, 2012.

M. Farlow, S. E. Arnold, and C. H. Van-dyck, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement, vol.8, issue.4, pp.261-71, 2012.

S. Ostrowitzki, D. Deptula, and L. Thurfjell, Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab, Arch Neurol, vol.69, issue.2, pp.198-207, 2012.

S. Salloway, R. Sperling, and S. Gilman, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, Neurology, vol.73, issue.24, pp.2061-70, 2009.

J. O. Rinne, D. J. Brooks, and M. N. Rossor, 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study, Lancet Neurol, vol.9, issue.4, pp.363-72, 2010.

K. Blennow, H. Zetterberg, and J. O. Rinne, Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease, Arch Neurol, vol.69, issue.8, pp.1002-1012, 2012.

F. M. Laferla, K. N. Green, and S. Oddo, Intracellular amyloid-beta in Alzheimer's disease, Nat Rev Neurosci, vol.8, issue.7, pp.499-509, 2007.

I. Klyubin, D. M. Walsh, and C. A. Lemere, Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo, Nat Med, vol.11, issue.5, pp.556-61, 2005.
DOI : 10.1038/nm1234

S. Lesne, M. T. Koh, and L. Kotilinek, A specific amyloid-beta protein assembly in the brain impairs memory, Nature, vol.440, issue.7082, pp.352-359, 2006.

I. C. Martins, I. Kuperstein, and H. Wilkinson, Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice, EMBO J, vol.27, issue.1, pp.224-257, 2008.
DOI : 10.1038/sj.emboj.7601953

URL : http://emboj.embopress.org/content/embojnl/27/1/224.full.pdf

N. Rudinskiy, J. M. Hawkes, and R. A. Betensky, Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease, Nature neuroscience, vol.15, issue.10, pp.1422-1431, 2012.
DOI : 10.1038/nn.3199

URL : http://europepmc.org/articles/pmc3458168?pdf=render

L. C. Souza, F. Corlier, and M. O. Habert, Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease, Brain, vol.134, pp.2036-2079, 2011.

W. E. Klunk, C. A. Mathis, J. C. Price, B. J. Lopresti, and S. T. Dekosky, Two-year follow-up of amyloid deposition in patients with Alzheimer's disease, Brain, vol.129, pp.2805-2812, 2006.

E. Callaway, Alzheimer's drugs take a new tack, Nature, vol.489, issue.7414, pp.13-17, 2012.
DOI : 10.1038/489013a

URL : http://www.nature.com:80/polopoly_fs/1.11343!/menu/main/topColumns/topLeftColumn/pdf/489013a.pdf

J. C. Dodart, K. R. Bales, and K. S. Gannon, Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model, Nature neuroscience, vol.5, issue.5, pp.452-459, 2002.
DOI : 10.1038/nn842

L. A. Kotilinek, B. Bacskai, and M. Westerman, Reversible memory loss in a mouse transgenic model of Alzheimer's disease, J Neurosci, vol.22, issue.15, pp.6331-6336, 2002.

E. B. Lee, L. Z. Leng, and B. Zhang, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice, The Journal of biological chemistry, vol.281, issue.7, pp.4292-4301, 2006.
DOI : 10.1074/jbc.m511018200

URL : http://www.jbc.org/content/281/7/4292.full.pdf

R. A. Sperling, J. Karlawish, and K. A. Johnson, Preclinical Alzheimer disease-the challenges ahead, Nat Rev Neurol, vol.9, issue.1, pp.54-62, 2012.
DOI : 10.1038/nrneurol.2012.241

URL : https://repository.upenn.edu/cgi/viewcontent.cgi?article=1110&context=neuroethics_pubs

C. Toly-ndour, G. Lui, M. M. Nunes, M. Bruley-rosset, P. Aucouturier et al.,

, MHC-independent genetic factors control the magnitude of CD4+ T cell responses to amyloid-beta peptide in mice through regulatory T cell-mediated inhibition, J Immunol, vol.187, issue.9, pp.4492-500, 2011.

G. Dorothee, M. Bottlaender, and E. Moukari, Distinct patterns of antiamyloid-beta antibodies in typical and atypical Alzheimer disease, Arch Neurol, vol.69, issue.9, pp.1181-1186, 2012.

X. Huang, A. D. Reynolds, R. L. Mosley, and H. E. Gendelman, CD 4+ T cells in the pathobiology of neurodegenerative disorders, J Neuroimmunol, vol.211, issue.1-2, pp.3-15, 2009.

T. Wyss-coray, Inflammation in Alzheimer disease: driving force, bystander or beneficial response, Nat Med, vol.12, issue.9, pp.1005-1020, 2006.

J. L. Grant, E. E. Ghosn, and R. C. Axtell, Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis, Science translational medicine, vol.4, issue.145, pp.145-150, 2012.

V. Berg, J. Prokop, S. Miller, and K. R. , Inhibition of IL-12/IL-23 signaling reduces

, Alzheimer's disease-like pathology and cognitive decline, Nat Med, vol.18, issue.12, pp.1812-1821, 2012.

R. O. Weller, D. Boche, and J. A. Nicoll, Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy, Acta Neuropathol, vol.118, issue.1, pp.87-102, 2009.

D. M. Wilcock and C. A. Colton, Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice, CNS & neurological disorders drug targets, vol.8, issue.1, pp.50-64, 2009.

D. Boche, E. Zotova, and R. O. Weller, Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, Brain, vol.131, pp.3299-310, 2008.

N. Melzer, A. Harder, and C. C. Gross, CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid beta-related angiitis, Arch Neurol, vol.69, issue.6, pp.773-780, 2012.

S. Kinkingnehun, M. Sarazin, S. Lehericy, E. Guichart-gomez, T. Hergueta et al., VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study, Neurology, vol.70, issue.23, pp.2201-2212, 2008.

C. Bernick, J. Cummings, R. Raman, X. Sun, P. Aisen et al., Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers, Arch Neurol, vol.69, issue.7, pp.293-300, 2011.

R. A. Sperling, P. S. Aisen, and L. A. Beckett, Toward defining the preclinical stages of

, Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, issue.3, pp.280-92, 2011.

R. S. Desikan, L. K. Mcevoy, and W. K. Thompson, Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau, Arch Neurol, vol.69, issue.6, pp.709-722, 2012.

I. Driscoll and J. Troncoso, Asymptomatic Alzheimer's disease: a prodrome or a state of resilience?, Curr Alzheimer Res, vol.8, issue.4, pp.330-335, 2011.

J. Kipnis, H. Cohen, M. Cardon, Y. Ziv, and M. Schwartz, T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions, Proc Natl Acad Sci U S A, vol.101, issue.21, pp.8180-8185, 2004.

M. Schwartz and R. Shechter, Systemic inflammatory cells fight off neurodegenerative disease, Nat Rev Neurol, vol.6, issue.7, pp.405-415, 2010.